5 studies on SLU-PP-332 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Shanghai Sigma Audley Ssa | 3 | — | View COA → |
| Nexaph | 2 | — | View COA → |
Manufacturers with published third-party certificates of analysis for SLU-PP-332. Open a vendor to see every batch we've verified.
This pilot study provides compelling evidence that Estrogen-Related Receptors (ERRs) represent a highly promising and previously under-explored therapeutic target for combating sarcopenia and disuse-induced muscle atr…
This study provides compelling evidence that a synthetic ERR agonist can effectively mitigate multiple symptoms of metabolic syndrome in a preclinical model, underscoring the significant therapeutic potential of targe…
This research highlights the therapeutic potential of targeting ERR pathways to combat heart failure by directly addressing its underlying metabolic dysfunction. By enhancing the heart's ability to generate energy and…
Free, no account — handy when you're working with SLU-PP-332.